Effect of Levamisole Supplementation on Tetanus Vaccination Response Rates in Hemodialysis Patients

Phase 2 Completed 40 enrolled Shiraz University of Medical Sciences

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Levamisole as an immunomodulator drug has been demonstrated to improve the immune response to Hepatitis B virus (HBV) vaccination in hemodialysis patients. The aim of this study was to evaluate the effect of levamisole supplementation on tetanus-diphtheria (Td) vaccine response rate in hemodialysis patients.

Timeline

Start: 2008-03
Primary completion: 2008-10
Completion: 2008-11

Outcome

Met primary endpoint

paper At 1 month, 13 out of 16 (81%) patients in the levamisole group as compared with six out of 18 (33%) patients in the placebo group developed protective anti-tetanus IgG levels (relative risk = 2.44, 95% confidence interval (CI) = 1.21, 4.88). PMID 24341659 ↗

Publications

Fallahzadeh MK, Sajjadi S, Singh N, Khajeh M, Sagheb MM. Effect of levamisole supplementation on tetanus vaccination response rates in haemodialysis patients: a randomized double-blind placebo-controlled trial. Nephrology (Carlton). 2014 Jan;19(1):27-31. doi: 10.1111/nep.12158.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Levamisole	Small molecule	100 mg	—

Indications

No indication recorded.